8-K: Moderna Navigates 2025 Challenges, Eyes 2026 Growth

Moderna reports strong operational execution and pipeline progress in 2025 despite a difficult U.S. environment, projecting up to 10% revenue growth in 2026.

Summary

• Navigated a difficult U.S. environment in 2025, focusing on operational execution, scientific progress, and disciplined financial management.
• Secured multiple regulatory approvals, now having three approved commercial products.
• Exceeded financial cash cost reduction commitments by nearly $1 billion in 2025.
• Projected revenue range for 2025 is $1.6 to $2.0 billion.
• Successfully launched mNEXSPIKE in the U.S. in mid-2025, which accounted for approximately 24% of all U.S. retail COVID vaccinations and nearly one-third among adults aged 65+ in 2025.
• Advanced pipeline significantly across seasonal vaccines, oncology, and rare diseases.
• Achieved three U.S. approvals in H1 2025: mNEXSPIKE (COVID for adults 65+ and high-risk 12-64), expanded indication for mRESVIA (RSV for adults 18-59 at increased risk), and supplemental approval for Spikevax (COVID-19 for high-risk children 6 months+).
• Reported strong Phase 3 influenza efficacy results for mRNA-1010, demonstrating superior relative vaccine efficacy compared to a standard-dose flu vaccine.
• Intismeran autogene (mRNA-4157) continued to advance across eight Phase 2 and Phase 3 trials, showing sustained benefit in recurrence-free survival (reduced risk by 49%) and distant metastasis or death (reduced risk by 62%) in melanoma patients when combined with KEYTRUDA.
• Marlborough manufacturing facility began supplying clinical batches of intismeran autogene in September 2025.
• mRNA-3927 (propionic acidemia) reached target enrollment in its registrational study.
• mRNA-3705 (methylmalonic acidemia) continued in U.S. FDA's START program, with a registrational study expected to begin in 2026.
• GAAP operating expenses declined from approximately $11.1 billion in 2023 to $7.2 billion in 2024, and are expected to decline further to less than $5.5 billion in 2025.
• Anticipates cash costs of approximately $4.2 billion for 2026 and $3.5 $3.9 billion for 2027.
• Secured a five-year, non-dilutive $1.5 billion term loan facility.
• Targeting cash breakeven in 2028.
• Expanded use of AI and digital tools, with over 4,000 GPTs written across the company.
• Expects to grow sales and deliver up to 10% revenue growth in 2026.
• Aims to diversify portfolio across oncology and rare diseases, with nine oncology clinical readouts anticipated over the next several years.
• Expects five-year Phase 2b melanoma data for intismeran in early 2026 and Phase 3 data potentially in 2026.
• Anticipates potential launch of intismeran with Merck as early as 2027.
• Targets approval for mRNA-4359 in 2028.
• Expects to launch first rare disease program (PA) by 2028, supported by data expected in 2026.
• Projects a 10% improvement in gross margins over the next three years due to increased automation and optimized capacity.

Sentiment

Score: 8

Explanation: The filing presents a highly positive outlook, emphasizing strong operational execution, significant cost reductions, successful product launches, and robust pipeline progress. While acknowledging a "difficult environment" in 2025, the overall tone and detailed plans for future growth, particularly in oncology and rare diseases, along with financial discipline, suggest strong confidence and positive momentum.

Positives

• Exceeded financial cash cost reduction commitments by nearly $1 billion in 2025.
• Secured multiple regulatory approvals, now having three approved commercial products.
• Successful U.S. launch of mNEXSPIKE, becoming the leading product in the U.S. retail channel and capturing significant market share (24% of all U.S. retail COVID vaccinations, nearly one-third for 65+ adults).
• Strong Phase 3 influenza efficacy results for mRNA-1010, demonstrating superior relative vaccine efficacy.
• Sustained long-term Phase 2b data for intismeran autogene in melanoma, showing 49% reduced risk of recurrence or death and 62% reduced risk of distant metastasis or death.
• Significant decline in GAAP operating expenses from $11.1 billion in 2023 to $7.2 billion in 2024, with a further expected decline to less than $5.5 billion in 2025.
• Secured a five-year, non-dilutive $1.5 billion term loan facility, bolstering the balance sheet.
• Expansion of global manufacturing footprint with new facilities in the UK, Canada, and Australia.
• Increased use of AI and digital tools, with over 4,000 GPTs developed internally, improving efficiency and reducing costs.
• Anticipated revenue growth of up to 10% in 2026.
• Projected 10% improvement in gross margins over the next three years.
• Recognition as a Top Employer by Science Careers for the eleventh consecutive year and a Best Place to Work by BioSpace.

Negatives

• Navigated a "difficult environment in the U.S. in 2025."
• International results varied by region, partly due to a "competitor contract still in effect in Europe."

Risks

• Forward-looking statements are neither promises nor guarantees and involve known and unknown risks, uncertainties, and other factors beyond Moderna's control.
• Actual results could differ materially from those expressed or implied by forward-looking statements.
• Risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and subsequent SEC filings.

Future Outlook

Moderna is well-positioned for its next chapter of growth with more stable commercial demand. The company outlined a three-year plan to build a large seasonal vaccine franchise and invest in oncology and rare diseases, aiming for 2028 cash breakeven. Commercial growth in 2026 is expected from annualized impact of long-term partnerships and continued strong uptake of mNEXSPIKE, targeting up to 10% revenue growth. Europe is seen as a significant market for respiratory virus vaccines in 2027 as a competitor contract lapses. By 2028, Moderna anticipates launching its flu/COVID combination vaccine and a potential novel Norovirus vaccine, expanding its seasonal franchise to as many as six approved products, alongside potential sales of intismeran in oncology and its therapeutic for PA patients. The company expects nine oncology clinical readouts over the next several years, with a potential launch of intismeran as early as 2027 and mRNA-4359 targeting approval in 2028. The first rare disease program (PA) is expected to launch by 2028. Increased automation and optimized capacity in the global manufacturing network are projected to drive a 10% improvement in gross margins over the next three years.

Management Comments

• "Our Mission—to deliver the greatest possible impact to people through mRNA medicines—remained our north star."
• "Despite this backdrop, 2025 was a productive year for Moderna."
• "Vaccines remain one of the most powerful tools in modern medicine to protect individual lives and strengthen the resilience and sustainability of health systems worldwide."
• "Moderna is well positioned for our next chapter of growth, now that we are experiencing more stable commercial demand."
• "We are entering 2026 with both the conviction and the capacity to deliver the next wave of growth and to shape a healthier future for people around the world."
• "This strong first-year performance underscores both the differentiated profile of the vaccine and the durability of the long-term COVID market." (referring to mNEXSPIKE)
• "We are proud to demonstrate the role our mRNA-based therapies could play in transforming the lives of those affected by cancer."
• "I believe 2026 will also be the year when the world sees the promise of Moderna as a leading oncology company." (Stéphane Bancel, CEO)
• "The future of Moderna lies in delivering on the enormous potential of mRNA science." (Stéphane Bancel, CEO)

Industry Context

The filing highlights the evolving respiratory vaccine market and the increasing importance of preventive medicine due to aging populations, workforce shortages, and rising care complexity in health systems. Moderna is positioning its mRNA vaccine platform as a key solution for infectious diseases and expanding into oncology and rare diseases, leveraging the broad therapeutic potential of mRNA science. The company's global manufacturing expansion and strategic partnerships reflect a trend towards regionalized supply chains and public health preparedness. The mention of a competitor contract in Europe indicates a competitive landscape in the vaccine market.

Comparison to Industry Standards

• mRNA-1010 demonstrated superior relative vaccine efficacy compared to a standard-dose flu vaccine.
• Intismeran in combination with Merck's KEYTRUDA showed a sustained benefit in recurrence-free survival and reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62% compared to KEYTRUDA alone, indicating strong performance against a known standard of care.
• mRNA-4359 showed an encouraging clinical signal in Stage 4 lung and skin cancer patients where approved immune-therapy treatments (like checkpoint inhibitors) did not work, suggesting potential for addressing high unmet needs beyond current standards.

Stakeholder Impact

• Shareholders: Positive impact due to strong operational execution, exceeding cost reduction targets, pipeline advancements, projected revenue growth, and a clear path to cash breakeven. The non-dilutive term loan also benefits shareholders by avoiding dilution.
• Patients: Positive impact through multiple regulatory approvals for vaccines (Spikevax, mRESVIA, mNEXSPIKE), advancements in oncology (intismeran, mRNA-4359) and rare diseases (mRNA-3927, mRNA-3705), expanding access to mRNA medicines globally.
• Employees: Positive impact indicated by recognition as a "Top Employer" and "Best Place to Work," and the company's commitment to enabling purposeful careers and amplifying talent with technology.
• Healthcare Systems: Positive impact through vaccines reducing hospitalizations, easing pressure on clinicians, and lowering long-term healthcare costs.
• Partners (e.g., Merck, international partners): Continued collaboration and strengthening of partnerships (e.g., UK, Canada, Australia, Brazil, Taiwan) for R&D, manufacturing, and market access.

Next Steps

• Continue to strengthen commercial execution and forecast sales in an endemic setting.
• Advance pipeline across diseases with high unmet need.
• Continue to streamline global manufacturing footprint and take down operating costs.
• Launch mNEXSPIKE in other countries.
• Pursue new potential long-term partnerships in Latin America and Asia-Pacific.
• Enter the flu vaccine market.
• Prepare for potential launch of intismeran with Merck as early as 2027.
• Continue to advance early-stage oncology programs, including mRNA-4359.
• Begin registrational study for mRNA-3705 (MMA) in 2026.
• Work toward a multi-indication oncology franchise with nine clinical readouts anticipated over the next several years.
• Expect five-year Phase 2b melanoma data for intismeran in early 2026.
• Expect Phase 3 data for intismeran potentially in 2026.
• Prepare for potential launch of intismeran as early as 2027.
• Target approval for mRNA-4359 in 2028.
• Launch first rare disease program in PA by 2028, supported by data expected in 2026.
• Implement new fill/finish capabilities in Norwood, Massachusetts, in 2027.
• Continue to look at innovative ways to use mRNA technology across oncology.
• Continue digital and robotics projects to strengthen operations, improve quality, and reduce costs in 2026.

Key Dates

Recommendation

The filing outlines a robust strategic plan with clear execution in 2025, including exceeding cost reduction targets and successful product launches like mNEXSPIKE. The company has a strong pipeline with significant advancements in seasonal vaccines, oncology, and rare diseases, backed by promising clinical data (e.g., mRNA-1010, intismeran). The projected revenue growth of up to 10% in 2026, coupled with a clear path to cash breakeven by 2028 and anticipated gross margin improvements, indicates strong financial discipline and future profitability. The non-dilutive capital raise further strengthens the balance sheet. The diversification into oncology and rare diseases, with multiple clinical readouts expected, positions Moderna for long-term value creation beyond its initial vaccine success. These factors collectively suggest a strong positive outlook for the company's stock.

Keywords

Moderna, MRNA, SEC filing, 8-K, shareholder letter, financial results, 2025 performance, 2026 outlook, mRNA vaccines, COVID-19 vaccine, Spikevax, mNEXSPIKE, RSV vaccine, mRESVIA, influenza vaccine, mRNA-1010, flu/COVID combination vaccine, mRNA-1083, Norovirus vaccine, oncology, intismeran autogene, mRNA-4157, melanoma, KEYTRUDA, rare diseases, propionic acidemia, mRNA-3927, methylmalonic acidemia, mRNA-3705, operating expenses, cash costs, revenue growth, manufacturing, AI, digital tools, pipeline, regulatory approvals